References
- Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136(5):E359-86
- Borel F, Konstantinova P, Jansen PLM. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol 2012;56(6):1371-83
- Li R, Qian N, Tao K, et al. MicroRNAs involved in neoplastic transformation of liver cancer stem cells. J Exp Clin Cancer Res CR 2010;29:169
- Xu Y, Xie Y, Wang X, et al. Identification of cancer stem cells from hepatocellular carcinoma cell lines and their related microRNAs. Oncol Rep 2013;30(5):2056-62
- Korhan P, Erdal E, Atabey N. MiR-181a-5p is downregulated in hepatocellular carcinoma and suppresses motility, invasion and branching-morphogenesis by directly targeting c-Met. Biochem Biophys Res Commun 2014;450(4):1304-12
- Duan X, Hu J, Wang Y, et al. MicroRNA-145: a promising biomarker for hepatocellular carcinoma (HCC). Gene 2014;541(1):67-8
- Shi L, Wang Z, Sun G, et al. miR-145 inhibits migration and invasion of glioma stem cells by targeting ABCG2. Neuromolecular Med 2014;16(2):517-28
- Ma S, Tang KH, Chan YP, et al. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 2010;7(6):694-707
- Zhang J, Luo N, Luo Y, et al. Li S. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb. Int J Oncol 2012;40(3):747-56
- Chai S, Ma S. Clinical implications of microRNAs in liver cancer stem cells. Chin J Cancer 2013;32(8):419-26
- Meng F, Glaser SS, Francis H, et al. Functional analysis of microRNAs in human hepatocellular cancer stem cells. J Cell Mol Med 2012;16(1):160-73
- Lai KW, Koh KX, Loh M, et al. MicroRNA-130b regulates the tumour suppressor RUNX3 in gastric cancer. Eur J Cancer Oxf Engl 1990;46(8):1456-63
- Guo C, Ding J, Yao L, et al. Tumor suppressor gene Runx3 sensitizes gastric cancer cells to chemotherapeutic drugs by downregulating Bcl-2, MDR-1 and MRP-1. Int J Cancer J Int Cancer 2005;116(1):155-60
- Fang L, Zhang H-B, Li H, et al. miR-548c-5p inhibits proliferation and migration and promotes apoptosis in CD90(+) HepG2 cells. Radiol Oncol 2012;46(3):233-41
- Ji J, Yamashita T, Budhu A, et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatol Baltim Md 2009;50(2):472-80
- Li L, Liu Y, Guo Y, et al. Regulatory MiR-148a-ACVR1/BMP circuit defines a cancer stem cell-like aggressive subtype of hepatocellular carcinoma. Hepatol Baltim Md 2015;61(2):574-84
- Sukowati CHC, Anfuso B, Torre G, et al. The expression of CD90/Thy-1 in hepatocellular carcinoma: an in vivo and in vitro study. PLoS One 2013;8(10):e76830
- Jia Q, Zhang X, Deng T, Gao J. Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(+)CD133(+) liver cancer stem cells. Cell Reprogramming 2013;15(2):143-50
- Sun Y-F, Xu Y, Yang X-R, et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatol Baltim Md 2013;57(4):1458-68
- Liu AM, Yao T-J, Wang W, et al. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open 2012;2(2):e000825